This inventor holds 3 USPTO granted patents. Top assignees: Guilford Pharmaceuticals, Inc., Nova Pharmaceutical Corporation, Scios Nova, Inc.. Active years: 1990-1994.
Location History:
- Belcamp, MD (US) (1990 - 1994)
- So. Belcamp, MD (US) (1994)
Company Filing History:
1 out of 98 
1 out of 23 
1 out of 40 Years Active: 1990-1994
Title: Michael J Pontecorvo: Innovator in Sigma Binding Site Agents
Introduction
Michael J Pontecorvo, an accomplished inventor based in Belcamp, MD, has made significant contributions to the field of pharmaceuticals through his innovative patents. With a total of three patents to his name, Pontecorvo has focused his research on developing sigma binding site agents, which play a crucial role in inhibiting certain biological activities in mammals.
Latest Patents
Pontecorvo's latest patents include breakthroughs in the formulation of sigma binding site agents. One of his notable inventions details intermediates for making sigma binding site agents, which are characterized by specific formulas wherein various components are defined in the specification, and W represents halogen. These novel intermediates are critical for the preparation of the binding site agents. Furthermore, his patent on sigma binding site agents outlines their potential utility in inhibiting sigma binding site-induced activity, which has implications for pharmaceutical compositions and methods associated with these agents.
Career Highlights
Throughout his career, Pontecorvo has worked with prominent companies in the pharmaceutical industry. He has been associated with Nova Pharmaceutical Corporation and Guilford Pharmaceuticals, Inc., where his innovative work has contributed to the advancement of therapeutic solutions.
Collaborations
Pontecorvo has collaborated with distinguished colleagues, including Ronald H Erickson and Kenneth J Natalie, Jr., sharing insights and expertise that have further propelled his research endeavors in pharmacology.
Conclusion
Michael J Pontecorvo continues to be a vital figure in the innovation of sigma binding site agents, enhancing our understanding and treatment of related medical conditions. His patented inventions not only reflect his dedication to biopharmaceutical advancements but also his role as a driving force behind significant innovations in the field.